BioCentury | Nov 5, 2015
Distillery Therapeutics

Therapeutics: Interleukin-17A (IL-17A); calcium channel

...compared with a serotype control mAb. Also in the mouse model, the calcium channel blocker diltiazem...
...and bone loss compared with vehicle. Next steps could include testing an IL-17A mAb or diltiazem...
...psoriatic arthritis and Phase I testing for rheumatoid arthritis (RA). The generic calcium channel blocker diltiazem...
BioCentury | Aug 18, 2014
Clinical News

Dolizem diltiazem cream: Development discontinued

...result of the FDA feedback in June on an NDA for the topical formulation of diltiazem...
...diltiazem cream ( VEN 307 ) Business: Gastrointestinal Molecular target: NA Description: Topical formulation of diltiazem...
BioCentury | Apr 7, 2014
Finance

1Q Stock Wrap-Up: Small but mighty

...in the sub-$200 million group, falling 67% in 1Q14. In February, the company said its diltiazem...
...a planned U.S. Phase III trial in the indication. Ventrus Biosciences Inc. (NASDAQ:VTUS)/S.L.A. Pharma AG Diltiazem...
BioCentury | Feb 17, 2014
Analyst Picks & Changes

Analyst picks & changes

...buy) -63% $1.58 Rivkind lowered her target to $2.50 from $6 after Ventrus said 2% diltiazem...
...request a pre-NDA meeting with FDA, has North American rights to the topical formulation of diltiazem...
BioCentury | Feb 17, 2014
Finance

Highlights of weekly biotech stock moves

...Clinical milestones Ventrus Biosciences Inc. (NASDAQ:VTUS) fell $2.76 (63%) to $1.62 on Wednesday after saying diltiazem...
BioCentury | Feb 17, 2014
Clinical News

Diltiazem cream: Phase III data

...double-blind, international Phase III trial in 434 patients with anal fissures showed that thrice-daily 2% diltiazem...
...baseline to week 4 vs. placebo (3.28 vs. 3.46 points). Ventrus said the efficacy of diltiazem...
...Diltiazem cream ( VEN 307 ) Business: Gastrointestinal Molecular target: NA Description: Topical formulation of diltiazem...
BioCentury | Feb 13, 2014
Clinical News

Ventrus cream misses in Phase III anal fissure trial

...Ventrus Biosciences Inc. (NASDAQ:VTUS) said thrice-daily 2% diltiazem cream ( VEN 307 ) missed the primary...
...in a 434-patient Phase III trial to treat anal fissures. Ventrus said the efficacy of diltiazem...
...the topical formulation of diltiazem hydrochloride from S.L.A. Pharma AG (Liestal, Switzerland). Oral formulations of diltiazem...
BioCentury | Jan 13, 2014
Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
BioCentury | Dec 9, 2013
Clinical News

Diltiazem cream: Completed Phase III enrollment

...patients with anal fissures in a double-blind, placebo-controlled, international Phase III trial evaluating thrice-daily 2% diltiazem...
...company reported data from its first Phase III trial showing that thrice-daily 2% and 4% diltiazem...
...Diltiazem cream ( VEN 307 ) Business: Gastrointestinal Molecular target: NA Description: Topical formulation of diltiazem...
BioCentury | May 13, 2013
Product Development

An association for dissociation

...mechanism of action and indication to Forest's cardiovascular portfolio, which includes two marketed products: Tiazac diltiazem...
Items per page:
1 - 10 of 143